Seminars in Cancer Biology

Article	Citations
Critical DNA damaging pathways in tumorigenesis	612
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	512
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	435
Emerging applications of bacteria as antitumor agents	396
Editorial Board	351
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	344
Deregulated transcription factors in the emerging cancer hallmarks	301
Multifaceted role of chemokines in solid tumors: From biology to therapy	273
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	264
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	240
Advances in biology and novel treatments of SCLC	234
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	233
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects	229
Small secretory proteins of immune cells can modulate gynecological cancers	219
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	219
Innovative trial design in precision oncology	214
The IL-1 family in tumorigenesis and antitumor immunity	207
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	201
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	198
Gut microbes in gastrointestinal cancers	180
Editorial Board	179
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	177
The emerging role of metabolic interventions in uveal melanoma	173
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	167
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	162

Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	161
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	158
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	154
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	153
Immune cellular components and signaling pathways in the tumor microenvironment	150
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	149
Anticancer properties of chimeric HDAC and kinase inhibitors	144
Origins and molecular effects of hypoxia in cancer	144
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	144
Genome chaos: Creating new genomic information essential for cancer macroevolution	140
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	137
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	137
Atrial fibrillation in cancer patients: Epidemiology, identification and management	135
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	133
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	132
The role of deiodinases on metabolic alteration in cancer	125
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	122
How far have we explored fungi to fight cancer?	121
Editorial Board	121
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	120
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	120
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	120
Anticancer natural products targeting immune checkpoint protein network	118
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	118
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	116
Editorial Board	116
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	115
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	114
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	112
Reprogramming of glycolysis by chemical carcinogens during tumor development	111
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	109
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	108
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	107
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	105
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	104
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	102
Editorial Board	100
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	100
Editorial Board	97
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	96
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	95
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	93
Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives	93
Metabolic reprogramming of tumor microenviroment by engineered bacteria	92
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	89
Editorial Board	87
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	87
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	87
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	86

Clinical utility of whole-genome sequencing in precision oncology	85
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	84
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	84
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	84
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?	84
Microbiota and lung cancer	83
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	83
The foundational framework of tumors: Gametogenesis, p53, and cancer	83
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	83
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	81
Advancements in small cell lung cancer	80
Analytical demands to use whole-genome sequencing in precision oncology	78
Holistic immunomodulation for small cell lung cancer	78
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	78
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	78
Microorganisms in cancer tertiary lymphoid structure formation	78
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	76
Editorial Board	76
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	75
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	74
Paradoxes of cancer: Survival at the brink	74
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	74
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	74
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	73
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	73
Anticancer activity of lactic acid bacteria	73
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	73
CRISPR/Cas mediated epigenome editing for cancer therapy	72
Excess body weight: Novel insights into its roles in obesity comorbidities	71
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	70
Editorial Board	70
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	70
Editorial Board	69
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	69
Thematic issue ‘tumor glycolysis’	68
Editorial Board	68
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	67
Human cell polyploidization: The good and the evil	67
SR-BI as a target of natural products and its significance in cancer	67
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	67
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	66
Deregulated transcription factors and poor clinical outcomes in cancer patients	66
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	66
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	66
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	65
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	65
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	65
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	65
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	65
Editorial Board	65
TGF-β, EMT, and resistance to anti-cancer treatment	65
The impact of VEGF on cancer metastasis and systemic disease	65
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	64
Gut microbiota and immunosenescence in cancer	63
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	63
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	63
The intricate nature of senescence in development and cell plasticity	62
Obesity, type 2 diabetes and cancers of the digestive system	62
Precision diagnostics in lymphomas – Recent developments and future directions	62
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	62
Transcriptional factors targeting in cancer stem cells for tumor modulation	61
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	61
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	60
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	59
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	59
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	59
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	59
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	58
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	58
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	58
Alternative splicing in EMT and TGF-β signaling during cancer progression	58
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	57
Artificial intelligence aids in development of nanomedicines for cancer management	57
cGAS/STING signalling pathway in senescence and oncogenesis	56
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	56
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	56
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	56
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	56
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	56
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	55

Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	55
Small cell lung cancer: Novel treatments beyond immunotherapy	54
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	53
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	53
Hedgehog signaling mechanism and role in cancer	53
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	53
Editorial Board	52
Editorial Board	52
The altered lipidome of hepatocellular carcinoma	52
Editorial Board	52
Vitamin D: What role in obesity-related cancer?	51
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	51
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	51
Precision medicine in pediatric solid cancers	50
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	50
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	50
Nanoparticles: Attractive tools to treat colorectal cancer	50
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	50
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	49
Ethical challenges of precision cancer medicine	49
Sphingolipids in embryonic development, cell cycle regulation, and stemness – Implications for polyploidy in tumors	49
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	49
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	49
Understanding RNA-binding proteins	48
Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes	48
The two sides of Hippo pathway in cancer	48
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	48
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells	48
Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics	47
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	47
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer	47
Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity	47
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions	47
The role of gut microbiota in obesity-related cancers	46
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	46
Nutrient sensing of mTORC1 signaling in cancer and aging	46
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	46
Targeting stemness of cancer stem cells to fight colorectal cancers	45
Editorial Board	45
Obesity and GEP-NEN: what’s new?	44
Epigenetic Regulation of Cancer Immune Cells	44
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	44
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis	44
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence	44
RB functions as a key regulator of senescence and tumor suppression	44
Vaginal microbiome and cervical cancer	44
Targeting cancer stem cells by nutraceuticals for cancer therapy	44
Harnessing computational spatial omics to explore the spatial biology intricacies	44
A systems and computational biology perspective on advancing CAR therapy	44
Therapy-driven clonal dynamics in chronic lymphocytic leukemia	44
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy	44
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations	44
Obesity and renal cell carcinoma: Biological mechanisms and perspectives	43
Special issue on “Excess body weight and cancer: Novel biologic insights and challenges”	43
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer	43
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard	43
The cell cycle revisited: DNA replication past S phase preserves genome integrity	42
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells	42
Status quo of Extracellular Vesicle isolation and detection methods for clinical utility	42
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	42
Expression of concern “Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies” [Semin. Cancer Biol. 111 (2025) 16–35]	41
Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy	41
Expression of concern “Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions” [Semin. Cancer Biol. 109 (	41
Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors	41
Insulin resistance in cancer risk and prognosis	41
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs	41
Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?	41
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	40
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany	40
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	40
Cancer cell populations	40
High-Throughput immunogenetics for precision medicine in cancer	40
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression	39
Expression of concern “T-cell senescence: Unlocking the tumor immune “Dark Box” – A multidimensional analysis from mechanism to tumor immunotherapeutic intervention” [Semin. Cancer Biol. 113 (2025) 19	39
Extracellular vesicles for precision medicine in prostate cancer – Is it ready for clinical translation?	39
Editorial: Regulating cell cycle-related activities: The right target for cancer therapy	39
The potential of liquid biopsy in the management of cancer patients	39
Expression of concern “DAMPs in immunosenescence and cancer” [Semin. Cancer Biol. 106–107 (2024) 123–142]	39
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer	39
Editorial Board	39
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]	39
Polyploidy in development and tumor models in Drosophila	38
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1	38
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review	38
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression	38
99mTC-sestamibi breast imaging: Current status, new ideas and future perspectives	37
Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis	37
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	37
Editorial Board	37
Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity	37
New opportunities and challenges of venom-based and bacteria-derived molecules for anticancer targeted therapy	37
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update	36
Targeting intratumoral hypoxia to enhance anti-tumor immunity	36
The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer	36